Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Symptoms and Disease Burden of ATTR

This slide deck provides an overview of the symptoms and disease burden of ATTR.

Impact of Long-Term Blood Pressure Variability on Adverse Cardiovascular Outcomes in High- and Low-Risk Populations

Safety and Tolerability of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients during Sodium Depletion or Irbesartan Coadministration

Neurofilament Light Chain in ATTR Amyloidosis with Cardiomyopathy: Analysis from the Phase 3 APOLLO-B Study

ATTR Diagnostic and Staging Tools

This deck highlights diagnostic and staging tools for assessing patients with ATTR.

The Science of RNA interference (RNAi)

This slide deck provides an overview of the science of RNA interference (RNAi), including mechanism of action and delivery platforms.

Diagnosis of PH1 in CKD or Dialysis Patients

This handout informs the consequences of PH1 systemic manifestations due to declining kidney function and how to diagnose PH1.

Renin-Angiotensin System (RAS) In Hypertension Video

This video highlights how the up-regulation of RAS contributes to hypertension. This resource is intended to support scientific exchange. The information provided is not intended to serve as recommendations for clinical practice.

Consistent antihypertensive efficacy of the RNA interference therapeutic zilebesiran: Subgroup results from the KARDIA-1 phase 2 study in patients with hypertension

ATTR Disease Management

This deck highlights management and monitoring of patients with ATTR.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.